

| REPORT DOCUMENTATION PAGE | | | | | Form Approved OMB No. 0704-0188 | |
|--|-----------------------------|--|---|------------------------------------|--|--|
| The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. | | | | | | |
| PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. | | | | | | |
| 1. REPORT DATE (DD-MM-YYYY) 12/10/2010 | | 2. REPORT TYPE Quarterly Technical Report | | | 3. DATES COVERED (From - To) 10/11/2010 - 12/11/2010 | |
| 4. TITLE AND SUBTITLE Human Neural Cell-Based Biosensor | | | | | 5a. CONTRACT NUMBER N00014-10-C-0066, Mod. P00001 | |
| | | | | | 5b. GRANT NUMBER | |
| | | | | | 5c. PROGRAM ELEMENT NUMBER | |
| | | | | | 5d. PROJECT NUMBER | |
| 6. AUTHOR(S) Stice, Steven L. Chilton, Jamie Powe, Allan | | | | | 5e. TASK NUMBER | |
| | | | | | 5f. WORK UNIT NUMBER | |
| | | | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) ArunA Biomedical, Inc. 425 River Road Athens, GA 30602 | | | | | 8. PERFORMING ORGANIZATION REPORT NUMBER TR-03112010.4 | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Director, Naval Research Lab Attn: Code 5596 4555 Overlook Avenue, SW Washington, D.C. 20375-5320 | | | | | 10. SPONSOR/MONITOR'S ACRONYM(S) DoD/ONR | |
| | | | | | 11. SPONSOR/MONITOR'S REPORT NUMBER(S) ONR 5252.235-9714 | |
| | | | | | | |
| 12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution is unlimited. | | | | | | |
| 13. SUPPLEMENTARY NOTES | | | | | | |
| 14. ABSTRACT Human neural progenitor cells have a strong potential for use as cell-based biosensors for environmental toxins. The overall goal of this project is to develop a human neural cell based biosensor using ArunA's neural progenitor cell line, hNP1™. In this report, we detail the progress in development for the following areas: (1) methods to isolate and enrich for neural progenitors using cell surface markers, (2) methods to directed differentiation of progenitors into dopaminergic neurons, motoneurons and astrocytes using defined medium conditions, (3) development of cell-based methods to detect botulinum toxin, and (4) development of fluorescence based assays for proliferation, mitochondrial function and reactive oxygen species generation as sensor elements. | | | | | | |
| 15. SUBJECT TERMS neurotoxicity, biosensor, neural cell | | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT UU | 18. NUMBER OF PAGES 5 | 19a. NAME OF RESPONSIBLE PERSON Steven L. Stice | |
| a. REPORT Unclassified | b. ABSTRACT Unclassified | c. THIS PAGE Unclassified | | | 19b. TELEPHONE NUMBER (Include area code) 706-583-0071 | |

Reset



425 River Road
Athens, GA 30605

**Quarterly Report
Human Neural Cell-Based Biosensor**

Date: December 10, 2010

Reporting Period: October 11, 2010 – December 11, 2010

Prepared for:
Office of Naval Research (ONR)
Director, Naval Research Lab
Attn: Code 5596
4555 Overlook Avenue, SW
Washington, D.C. 20375-5320

Contract Number: N00014-10-C-0066, Amendment/Modification P00001

Submitted by:
Dr. Steven L. Stice, Principle Investigator
ArunA Biomedical, Inc.
425 River Road
Athens, GA 30602
Phone: 706-583-0071
Fax: 706-262-2821
Email: ssstice@arunabiomedical.com

Distribution Statement A:
Approved for public release; distribution is unlimited.

UNCLASSIFIED

Distribution of Quarterly Report

| ADDRESSEE | DODAAC CODE | REPORT ENCLOSED | NUMBER OF COPIES | |
|--|-------------|-----------------------|----------------------------|--|
| | | | UNCLASSIFIED/ UNLIMITED | UNCLASSIFIED/ LIMIT ED AND CLASSIFIED |
| Program Officer: Dr. Laura Kienker ONR Code: 342 E-Mail: laura.kienker@navy.mil | N00014 | Full technical report | 1 | 1 |
| Administrative Contracting Officer: Office of Naval Research ONR 0254: Russelle Dunson 875 North Randolph St. Arlington, VA 22203-1995 E-mail: russelle.dunson@navy.mil | S1103A | SF 298 only | 1 | 1 |
| Director, Naval Research Lab Attn: Code 5596 4555 Overlook Avenue, SW Washington, D.C. 20375-5320 E-mail: reports@library.nrl.navy.mil | N00173 | Full technical report | 1 | 1 |
| Defense Technical Information Center 8725 John J. Kingman Road STE 0944 Ft. Belvoir, VA 22060-6218 E-mail: tr@dtic.mil | HJ4701 | Full technical report | 2 | 2 |

Summary

Human neural progenitor cells have a strong potential for use as cell-based biosensors for environmental toxins. The overall goal of this project is to develop a human neural cell based biosensor using ArunA's neural progenitor cell line, hNP1™. In this report, we detail the progress in development for the following areas: (1) methods to isolate and enrich for neural progenitors using cell surface markers, (2) methods to directed differentiation of progenitors into dopaminergic neurons, motoneurons and astrocytes using defined medium conditions, (3) development of cell-based methods to detect botulinum toxin, and (4) development of fluorescence based assays for proliferation, mitochondrial function and reactive oxygen species generation as sensor elements.

(1) Isolation and enrichment of mature neural cells using cell surface markers

Our previous studies using flow cytometry showed that our hNP1™ neural progenitors express three particular cell surface markers that could be used as tools for isolation and enrichment of human neural progenitor cells from a mixed population of cells, such as induced pluripotent stem cells. To corroborate our flow cytometry results, we examined the subcellular localization of these proteins by immunofluorescence and found that ~100% of the hNP1™ cells were positive for all the markers with the expected plasma membrane localization. We think that any quantitative differences between immunofluorescence and flow cytometry results (e.g., ~100% versus ~75%, respectively, for one of the markers) reflect differences in detection sensitivity between the two methods, warranting some additional optimization of the flow cytometry procedure. We are now working on optimizing cell sorting methods using these cell surface epitopes with magnetic beads to determine which sorting marker will work best going forward. Studies using one of the markers have been completed and will be submitted for publication shortly.

(2) Directed differentiation using defined media conditions

We are continuing development of methods for directed differentiation of neural progenitors into dopaminergic, motoneurons and astrocytes. Dopaminergic neurons are a target cell type for mitochondrial toxins, such as rotenone, MPTP, etc. and will be a good model system for environmental neurotoxins and neurodegenerative disorders, such as Parkinson's disease. Motor neurons are the target cell type for botulinum toxin and would be a useful cell type for the detection of this potential bioterrorism agent. Astrocytes, a type of glia, can be used to promote synapse formation and to support the long-term survival of neurons in a cell-based biosensor. We are now setting up screening assays to measure differentiation efficacy and optimizing differentiation protocols to improve yields for the target cell types.

(3) Development of cell based methods to detect botulinum toxin

The development of an hN2™ cell based sensor for botulinum toxin has begun. hN2™ cells are derived from hNP1™ progenitors using a proprietary differentiation method. Early experiments demonstrate that we are able to detect SNAP-25 in hN2™ cells using Western blotting and that treatment of hN2™ with botulinum toxin A causes the cleavage of SNAP-25. Further investigations into method development and dosage sensitivity are underway.

(4) Development of fluorescence based assays as sensor elements for neurotoxicity

Currently, we are developing fluorescence based assays to examine mitochondrial health, reactive oxygen species generation and cell migration in our neural progenitor and differentiated neural cells. These assays would serve as sensor elements in cell-based biosensors. All three assay methods continue to show promise as potential sensor elements.

We plan to adapt the Alamar Blue assay for use with both hNP1™ and hN2™ cells. The Alamar Blue assay measures the activity of mitochondrial reductases, providing an indicator of mitochondrial health for the non-proliferative hN2™ cells and both mitochondrial health and cell number for the proliferative hNP1™ cells. We have optimized conditions for use with hNP1™ and will next test a small set of known neurotoxins to complete proof-of-concept studies. Adaptation using hN2™ will begin shortly.

In addition, we are continuing development of a reactive oxygen species (ROS) assay as described in the last progress report (Q3 2010). Our results to date continue to suggest that certain growth factors reduce cellular levels of ROS in neural progenitors and confer a neuroprotective effect. Testing of select toxins with this assay is underway.

In collaboration with Platypus Technologies, we have also begun development of a cell migration assay using neural progenitors. Migration of neural progenitors to their proper location in the central nervous system is a critical process for normal development and can be affected by environmental toxins. Early results demonstrate that cytochalasin D, an actin polymerization inhibitor, can block hNP1™ migration. Our preliminary results also show that certain individual growth factors and combinations thereof can have potent chemokinetic effects on hNP1™ migration. Further development of this assay and testing with cell migration stimulators and inhibitors is underway. Our progress to date will be presented in poster format at the American Society for Cell Biology meeting in Philadelphia, PA on December 14th 2010.